A future household name across Europe?

(Full access for Lifetime Members only)

Exclusive report for Lifetime Members only

Exclusive report for Lifetime Members only

A future household name across Europe?

31 May 2020

What readers said about this report

The company featured in this exclusive report should benefit mightily from a secular growth trend – one that will be unheard of by many.

It's a secular growth trend because this industry is still in its infancy. During the 2020s, it should come into its own. The company's underlying technology could eventually help treat 80 different diseases. The World Economic Forum believes it "could be the medical innovation of the century", and its market is currently growing at 36% p.a.

So far, only 2% of all Europeans are using this new technology.

In Taiwan, it's already 23%. In Singapore, it's 10%. The US is behind this time, but at least it has already recorded a 4% market penetration – double that of Europe.

There is a good chance that the entire world will eventually follow the forward-thinking people of Taiwan and Singapore. Europe, too, should catch up. Needless to say, COVID-19 plays its part to keep healthcare and technology at the front of people's minds.

Undervalued-Shares.com has managed to locate the one company that is now almost certain to become the European champion. It is already involved in a transaction that should make it the global #3 before 2020 is over. It'll stand alongside its two main competitors from the US and China.

Incredibly, few seem to have noticed yet.

Where's the catch?

The company in question lacks trading liquidity – unlike most other companies that are usually featured on this website.

This opportunity is therefore exclusively available to Undervalued-Shares.com Lifetime Members.

Not a Lifetime Member yet? Sign up for a Membership - just USD 999/one-off.
Already a Lifetime Member? Log into your account to download the report.

|  What readers said about this report

Jakob H.
April 2021

Thank you again for yet another interesting analysis that you present to us. I like the fact that you look for undervalued stocks that is also related to long term trends and is therefore also likely to be long term compounders. I am now invested in (company name hidden by Undervalued-Shares.com), (company name hidden by Undervalued-Shares.com), JET, (company name hidden by Undervalued-Shares.com), (company name hidden by Undervalued-Shares.com) and (company name hidden by Undervalued-Shares.com). So you definitely have had an impact on my portfolio for the last year or so. I view your reports as inspiration for a modern Munger-like investing approach.

Based on the stories on Poland growth story i also invested in Mo-bruk (Polish) in the ESG area, as i believe that the increased wealth will result in a continued improvement of ESG in generel terms.

Nicholas M.
August 2020

I really enjoyed reading about the (company name hidden by Undervalued-Shares.com) (the (company name hidden by Undervalued-Shares.com)) which I will be investing by the end of this summer.

Helmut F.
July 2020

Regarding (company name hidden by Undervalued-Shares.com), we do really agree very well and you had already correctly anticipated many things that have materialised over the last few weeks – for my own analysis I already had more information with the present mandatory offer 🙂

Alexander G.
July 2020

I've now read your report on (company name hidden by Undervalued-Shares.com). Very well and interestingly written (detailed as always).

Markus M.
June 2020

Your report on (company name hidden by Undervalued-Shares.com) / (company name hidden by Undervalued-Shares.com) was top notch!!!

Tom R.
June 2020

Many thanks for your great report on (company name hidden by Undervalued-Shares.com) and (company name hidden by Undervalued-Shares.com). As a (company name hidden by Undervalued-Shares.com) shareholder, I am pleased that you have uncovered the connection between AOC and the two companies.

Christian K.
June 2020

Big praise for the (company name hidden by Undervalued-Shares.com) / (company name hidden by Undervalued-Shares.com) article. For me this has been one of the best and most interesting articles in a long time. Not that your other reports aren’t interesting, I find them all a great asset so far. But as a father of 2 small children who are (company name hidden by Undervalued-Shares.com) customers, the report gave me an extremely strong insight into the background of this medical technology.

Robert P.
June 2020

Thank you very much. I've even started reading the report. I've already got to say - it was worth it. This is a very interesting topic, and as a private investor you don't really have it on your radar as an investment.

Alexander M.
June 2020

It was hard for me to buy into (company name hidden by Undervalued-Shares.com), and so I bought (company name hidden by Undervalued-Shares.com) instead. When I suggested perhaps the Polish Banking sector this is not what I had in mind, but I agree this is a good find.

Mackenzie B.
June 2020

Very very interesting. The subscription business model in this context was what got me out of my seat. Will be interesting to see how this unfolds.

Thoralf D.
May 2020

Top report. I'd already been interested in (company name hidden by Undervalued-Shares.com) years ago and then on and off but never consistently and then lost sight of it again. Highly interesting topic.

l  Report updates

Not a Member yet? Sign up for a Membership.
Already a Member? Log into your account to download the report updates.

23 September 2021

Report Update (PDF - 0.3MB)

9 August 2021

Report Update (PDF - 0.3MB)

1 June 2021

Report Update (PDF - 0.1MB)

18 May 2021

Report Update (PDF - 0.2MB)

7 April 2021

Report Update (PDF - 0.2MB)

18 February 2021

Report Update (PDF - 0.2MB)

5 January 2021

Report Update (PDF - 0.3MB)

9 October 2020

Report Update (PDF - 0.5MB)

17 July 2020

Report Update (PDF - 0.1MB)

2 July 2020

Report Update (PDF - 3.3MB)

Most recent

The Economist: a good investment?

The Economist: a good investment?

It’s little-known, but The Economist has over 1,000 shareholders. It’s akin to an exclusive club, which rather wants to keep you out. Will you be able to buy stock regardless – and could a proper IPO beckon?

read more

Latest reports (for Members only)

Bayer AG: similar to buying Volkswagen two years ago?

Bayer AG: similar to buying Volkswagen three years ago?

German blue chip Bayer is currently down and out. 2022 should bring a turnaround, though, similar to the one seen at Volkswagen.

A groundfloor opportunity in gaming and esports

A groundfloor opportunity in gaming and esports

This European entertainment champion is looking to turn itself into a global giant - and could gain 125% by mid-2022.

Novavax: The "best" coronavirus vaccine and an undervalued stock?

Novavax: The "best" coronavirus vaccine and an undervalued stock?

Can coronavirus vaccine maker Novavax profit from the vast majority of unvaccinated people, and make vaccine sceptics fall in love with it?